Applied Therapeutics Stock Performance
| APLT Stock | USD 0.65 0 0.46% |
The firm shows a Beta (market volatility) of 2.45, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Applied Therapeutics will likely underperform. At this point, Applied Therapeutics has a negative expected return of -2.99%. Please make sure to confirm Applied Therapeutics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Applied Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Applied Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | APLT INVESTOR ALERT Kirby McInerney LLP Notifies Applied Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit | 01/30/2025 |
2 | Deadline Alert Applied Therapeutics, Inc. ... | 02/03/2025 |
3 | Disposition of 28117 shares by Constantine Chinoporos of Applied Therapeutics at 0.61 subject to Rule 16b-3 | 02/06/2025 |
4 | APLT CLASS ACTION Applied Therapeutics 80 percent Stock Drop Triggers Class Action -- Contact BFA Law before February 18 Deadline | 02/10/2025 |
5 | APLT DEADLINE ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Applied Therapeutics, Inc. ... | 02/11/2025 |
6 | DEADLINE ALERT Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Applied ... | 02/12/2025 |
7 | APLT LAWSUIT ALERT Levi Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | 02/13/2025 |
8 | JANUS HENDERSON GROUP PLC Significantly Reduces Stake in Applied Therapeutics Inc | 02/14/2025 |
| Begin Period Cash Flow | 16.7 M |
Applied |
Applied Therapeutics Relative Risk vs. Return Landscape
If you would invest 893.00 in Applied Therapeutics on November 19, 2024 and sell it today you would lose (828.30) from holding Applied Therapeutics or give up 92.75% of portfolio value over 90 days. Applied Therapeutics is currently does not generate positive expected returns and assumes 11.2788% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Applied, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Applied Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Applied Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Applied Therapeutics, and traders can use it to determine the average amount a Applied Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2651
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | APLT |
Estimated Market Risk
| 11.28 actual daily | 96 96% of assets are less volatile |
Expected Return
| -2.99 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.27 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Applied Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Applied Therapeutics by adding Applied Therapeutics to a well-diversified portfolio.
Applied Therapeutics Fundamentals Growth
Applied Stock prices reflect investors' perceptions of the future prospects and financial health of Applied Therapeutics, and Applied Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Applied Stock performance.
| Return On Equity | -4.73 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (243.80) % | ||||
| Current Valuation | (21.61 M) | ||||
| Shares Outstanding | 116.36 M | ||||
| Price To Earning | (7.46) X | ||||
| Price To Book | 12.78 X | ||||
| Price To Sales | 54.68 X | ||||
| Revenue | 9.99 M | ||||
| Gross Profit | (52.56 M) | ||||
| EBITDA | (64.53 M) | ||||
| Net Income | (119.76 M) | ||||
| Cash And Equivalents | 67.72 M | ||||
| Cash Per Share | 1.41 X | ||||
| Total Debt | 777 K | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 1.49 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (55.17 M) | ||||
| Earnings Per Share | (1.42) X | ||||
| Market Capitalization | 75.28 M | ||||
| Total Asset | 54.83 M | ||||
| Retained Earnings | (468.59 M) | ||||
| Working Capital | (16.8 M) | ||||
| Current Asset | 37.74 M | ||||
| Current Liabilities | 11.19 M | ||||
About Applied Therapeutics Performance
Assessing Applied Therapeutics' fundamental ratios provides investors with valuable insights into Applied Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Applied Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (204.85) | (215.09) | |
| Return On Tangible Assets | (2.51) | (2.64) | |
| Return On Capital Employed | 4.54 | 4.77 | |
| Return On Assets | (2.51) | (2.64) | |
| Return On Equity | 8.03 | 8.43 |
Things to note about Applied Therapeutics performance evaluation
Checking the ongoing alerts about Applied Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Applied Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Applied Therapeutics generated a negative expected return over the last 90 days | |
| Applied Therapeutics has high historical volatility and very poor performance | |
| Applied Therapeutics has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 9.99 M. Net Loss for the year was (119.76 M) with loss before overhead, payroll, taxes, and interest of (52.56 M). | |
| Applied Therapeutics currently holds about 67.72 M in cash with (55.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Applied Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: JANUS HENDERSON GROUP PLC Significantly Reduces Stake in Applied Therapeutics Inc |
- Analyzing Applied Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Applied Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Applied Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Applied Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Applied Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Applied Therapeutics' stock. These opinions can provide insight into Applied Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Applied Stock Analysis
When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.